<Suppliers Price>

N-(2,6-Dimethylphenl)-2-Piperidine Carboxamide

Names

[ CAS No. ]:
15883-20-2

[ Name ]:
N-(2,6-Dimethylphenl)-2-Piperidine Carboxamide

[Synonym ]:
N-(2',6'- Dinethylphenyl)-2-piperidinecarboxamide HCL
UNII:NF8RN1V7VM
Mepivacaine impurity B
Desbutylbupivacaine
(RS)-N-(2,6-Dimethylphenyl)piperidine-2-carboxamide,Desbutylbupivacaine
N-(2,6-Dimethylphenyl)-2-piperidinecarboxamide
N-Desbutyl Bupivacaine
MFCD08458869
2',6'-Pipecoloxylidide
2-Piperidinecarboxamide, N-(2,6-dimethylphenyl)-
N-(2,6-Dimethylphenyl)piperidine-2-carboxamide
N-(2',6'-Dimethylphenyl)-2-piperidinecarboxamide
(RS)-N-(2,6-Dimethylphenyl)piperidine-2-carboxamide
N-(2,6-DIMETHYLPHENYL ) -PIPERIDINE-2-CARBOXYLIC AMIDE
Bupivacaine Impurity 4

Chemical & Physical Properties

[ Density]:
1.1±0.1 g/cm3

[ Boiling Point ]:
392.3±42.0 °C at 760 mmHg

[ Melting Point ]:
114-117ºC

[ Molecular Formula ]:
C14H20N2O

[ Molecular Weight ]:
232.321

[ Flash Point ]:
149.0±28.0 °C

[ Exact Mass ]:
232.157562

[ PSA ]:
41.13000

[ LogP ]:
2.29

[ Vapour Pressure ]:
0.0±0.9 mmHg at 25°C

[ Index of Refraction ]:
1.567

[ Storage condition ]:
-20°C Freezer

MSDS

Toxicological Information

CHEMICAL IDENTIFICATION

RTECS NUMBER :
TM6076000
CHEMICAL NAME :
2-Piperidinecarboxamide, N-(2,6-dimethylphenyl)-
CAS REGISTRY NUMBER :
15883-20-2
BEILSTEIN REFERENCE NO. :
0206391
LAST UPDATED :
199612
DATA ITEMS CITED :
2
MOLECULAR FORMULA :
C14-H20-N2-O
MOLECULAR WEIGHT :
232.36

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
140 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
CEXPB9 Clinical and Experimental Pharmacology and Physiology. (Blackwell Scientific Publications, (Australia) Pty Ltd., 107 Barry St., Carlton, Vic. 3053, Australia) V.1- 1974- Volume(issue)/page/year: 21,997,1994
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
45 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
EPXXDW European Patent Application. (U.S. Patent and Trademark Office, Foreign Patents, Washington, DC 20231) Volume(issue)/page/year: #0155176

Safety Information

[ Symbol ]:

GHS06

[ Signal Word ]:
Danger

[ Hazard Statements ]:
H301

[ Precautionary Statements ]:
Missing Phrase - N15.00950417

[ Hazard Codes ]:
Xi: Irritant;

[ Risk Phrases ]:
25

[ Safety Phrases ]:
45

[ RIDADR ]:
UN 2811 6.1 / PGIII

[ RTECS ]:
TM6076000

[ HS Code ]:
2933399090

Synthetic Route

Precursor & DownStream

Customs

[ HS Code ]: 2933399090

[ Summary ]:
2933399090. other compounds containing an unfused pyridine ring (whether or not hydrogenated) in the structure. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

Articles

Kinetics of bupivacaine after clonidine pretreatment in mice.

Can. J. Anaesth. 42(5 Pt 1) , 434-7, (1995)

Previous studies have reported that clonidine pretreatment causes an increase in the local anaesthetic activity of bupivacaine. This study was designed to document possible changes in the pharmacokine...

Population pharmacokinetic analysis of ropivacaine and its metabolite 2',6'-pipecoloxylidide from pooled data in neonates, infants, and children.

Br. J. Anaesth. 107(3) , 409-24, (2011)

The aim was to characterize ropivacaine and 2',6'-pipecoloxylidide (PPX) pharmacokinetics and factors affecting them in paediatric anaesthesia.Population pharmacokinetics of ropivacaine and its active...

Bupivacaine kinetics during hyperthermia in rats.

Can. J. Anaesth. 41(3) , 253-6, (1994)

The aim of this study was to document possible alterations of bupivacaine pharmacokinetic behaviour in rats during hyperthermia. Two groups of Wistar AF IO PS male rats (Group A = normothermic control...


More Articles


Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.